Nanotechnology in Drug Delivery Technological Improvements and Novel Approaches to Fulfill High Po

Document Sample
Nanotechnology in Drug Delivery Technological Improvements and Novel Approaches to Fulfill High Po Powered By Docstoc
					      Nanotechnology in Drug Delivery - Technological
 Improvements and Novel Approaches to Fulfill High Potential
 Reference Code: GBIHC043MR                                                                             Publication Date: December 2010


                                     The nano-enabled drug delivery market has seen high growth in the market and is expected to
                                     grow at a faster rate in the near future. The market will witness increased competition, high
   High unmet need in the            investment from venture capitalists and government. The M&A and licensing landscape will see
   nano-enabled drug                 significant changes in the future. This is because the market is expected to become more lucrative.
   delivery market offers
   tremendous scope for new          The Nano-Enabled Market Represents Significant Opportunities and High Level of Unmet
   entrants and existing             Needs
   players
                                      Nanotechnology in Drug Delivery Market, Opportunity and Unmet Needs, 2010


                                                      Opportunities                                         Unmet Needs

                                                  Opportunities for
                                                                                                                 Nanotoxicity of
                                                  New Dug Delivery
                                                                                                                 Nanomaterials
                                                    Companies




                                                                                                                     Need of
                                                   Market Growth               Opportunity and                    Understanding
                                                                                Unmet Needs                     Biological behavior




                                                                                                                     Need of
                                                                                                                 Understanding
                                                      Licensing                                                Distribution Pattern
                                                     Opportunity                                                of Nanomaterials




                                      Source: GBI Research




                                     The nano-enabled drug delivery market has plenty of opportunities and a high level of unmet need.
                                     Opportunities for creating a new drug delivery company are tremendous. Many small companies
                                     have launched the technology to develop novel methods for exploiting nanotechnologies in drug
                                     delivery. In the past, companies have been dedicated to the nano-enabled drug delivery that has
                                     been popping up all over the world.
                                     The creation of new companies will not only increase the investment and market growth, but also
                                     increase the competition in the market place. In addition, the emergence of new companies will
                                     provide licensing and merger and acquisition (M&A) opportunities for larger pharmaceutical
                                     markets.
                                     The market is also characterized by high levels of unmet need. This is primarily because
                                     development in this area is in its initial stages and has a significant number of unaddressed issues
                                     such as nanotoxicity, biological behavior and distribution pattern of nanoparticles. These unmet
                                     needs represent a significant opportunity for companies to explore.


Nanotechnology in Drug Delivery - Technological Improvements                                              GBIHC043MR / Published DEC 2010
and Novel Approaches to Fulfill High Potential
                                                                                                                                       Page 1
                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                     In summary, high growth in the nano-enabled drug delivery markets will provide significant
                                     opportunities for companies.
                                     Increased Investment and Emerging Business Models Will Support the Market Growth
                                     The increasing investment in the nano-enabled drug delivery market has significantly driven the
                                     market. Funding for nanotechnology programs increased during the administration of George Bush.
                                     The nanotechnology funding is expected to increase significantly in the future. Among all the major
                                     geographies, the European government is investing more in nanotechnology R&D. This suggests
                                     that there will be increased governmental support for nanotechnology R&D. In addition, increase in
                                     early stage venture capital will also affect the market positively.
                                     Careful Approach of Regulator towards Nanotechnology is Negatively Affecting the Market

                                      Challenges Facing Regulators Regarding Nanotechnology




                                                    Address                                                      Promote Growth
                                                   Concerns                                                            in
                                                    Related                                                      Nanotechnology
                                                 to Health and
                                                  Environment




                                                                                                                 Assess whether
                                                Finding Criteria                                                 New Regulations
                                                for Segregating          Regulatory Challenges                   are Required or
                                                 Nanoparticles             in Nanotechnology                          Not




                                                 Regulations                                                       Co-operation
                                               across the Globe                                                      between
                                                  should be                                                         Domestic
                                                    in-sync                                                         Regulators




                                      Source: GBI Research




                                     The toxicity increases due to increased surface area for the particle when the size is reduced. This
                                     gives rise to concerns about the possible negative impact on public health and environment due to
                                     increased use of nanotechnology enabled products. Nanotechnology is increasingly being
                                     employed in industries such as medicine, cosmetics, food, semiconductor devices, energy and
                                     telecommunications due to the advantages it provides over the conventional technology. As the
                                     use of nanotechnology progresses, the risk of exposure to the population also rises. This has led a
                                     cautious approach of regulators toward nanotechnology.




Nanotechnology in Drug Delivery - Technological Improvements                                              GBIHC043MR / Published DEC 2010
and Novel Approaches to Fulfill High Potential
                                                                                                                                       Page 2
                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                     1         Table of Contents
                                     1   Table of Contents ........................................................................................................................ 3
                                         1.1    List of Tables..................................................................................................................... 6
                                         1.2    List of Figures ................................................................................................................... 6
                                     2   Nanotechnology in Drug Delivery – Introduction.......................................................................... 7
                                         2.1    Introduction ....................................................................................................................... 7
                                         2.2    GBI Research Report Guidance ....................................................................................... 8
                                     3   Application of Nanotechnology in Drug Delivery .......................................................................... 9
                                         3.1    Current Applications of Nano-enabled Drug Delivery........................................................ 9
                                            3.1.1    Nano-engineered drugs ............................................................................................. 9
                                            3.1.2    Nano-carriers ........................................................................................................... 10
                                         3.2    Future Applications of Nano-enabled Drug Delivery ....................................................... 11
                                            3.2.1    Gene and Vaccine Delivery ..................................................................................... 11
                                            3.2.2    Controlled-Release Devices .................................................................................... 12
                                            3.2.3    Increased Biocompatibility ....................................................................................... 12
                                            3.2.4    Improved Drug Bioavailability and Solubility ............................................................ 12
                                            3.2.5    Applied Diagnosis, Etiology, Prognosis and Therapy (ADEPT) ............................... 12
                                            3.2.6    Tissue Specific Delivery .......................................................................................... 12
                                     4   Nanotechnology in Drug Delivery – Case Studies ..................................................................... 13
                                         4.1    Abraxis Bioscience, Inc. – Paclitaxel-Albumin Nanoparticles (Abraxane) ....................... 13
                                         4.2    Nanospectra Biosciences– AuroShell Particles .............................................................. 13
                                         4.3    Calando Pharmaceuticals, Inc. – RONDEL Technology ................................................. 13
                                         4.4    Starpharma Holdings, Ltd. – Dendrimer-Based VivaGel ................................................. 14
                                         4.5    Mersana Therapeutics: Fleximer – Camptothecin Conjugate ......................................... 14
                                         4.6    Elan Corporation – NanoCrystal Technology .................................................................. 14
                                     5   Nanotechnology in Drug Delivery – Market Characterization .................................................... 16
                                         5.1    Introduction ..................................................................................................................... 16
                                         5.2    Nano-enabled Drug Delivery Market Drivers................................................................... 16
                                            5.2.1    Clinical Benefits of Nano-enabled Drug delivery...................................................... 16
                                            5.2.2    Value Addition to Existing Pharmaceutical Products through Reformulation ........... 16
                                            5.2.3    Strong Pipeline Portfolio .......................................................................................... 16
                                         5.3    Nano-Enabled Drug Delivery Market Barriers ................................................................. 17
                                            5.3.1    Poor R&D Facilities and Time Gap between Research and Commercialization ...... 17
                                            5.3.2    Lack of Consistent Policy on Technology Transfer and Lack of Capacity to Produce
                                                     Products .................................................................................................................. 17
                                            5.3.3    Regulatory Hindrance .............................................................................................. 17
                                         5.4    Opportunity and Unmet Need – Drug Delivery ................................................................ 18
                                            5.4.1    Opportunities ........................................................................................................... 18
                                            5.4.2    Unmet Need ............................................................................................................ 18
                                         5.5    Selected Nano-Enabled Therapeutics Approved by the FDA ......................................... 20
                                            5.5.1    Doxil (Caelyx) .......................................................................................................... 20
                                            5.5.2    Abraxane ................................................................................................................. 21
                                            5.5.3    AmBisome ............................................................................................................... 22
                                            5.5.4    Diprivan ................................................................................................................... 23
                                            5.5.5    Triglide ..................................................................................................................... 24
                                            5.5.6    Myocet ..................................................................................................................... 25
                                            5.5.7    DepoCyt .................................................................................................................. 26
                                            5.5.8    DaunoXome............................................................................................................. 27
                                            5.5.9    Estrasorb ................................................................................................................. 27
                                            5.5.10 Macugen .................................................................................................................. 28
                                            5.5.11 Abelcet .................................................................................................................... 29
                                            5.5.12 Adagen .................................................................................................................... 30
                                            5.5.13 Pegasys ................................................................................................................... 30
                                            5.5.14 Somavert ................................................................................................................. 32


Nanotechnology in Drug Delivery - Technological Improvements                                                                         GBIHC043MR / Published DEC 2010
and Novel Approaches to Fulfill High Potential
                                                                                                                                                                            Page 3
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                           5.5.15 Neulasta .................................................................................................................. 33
                                           5.5.16 Copaxone ................................................................................................................ 34
                                           5.5.17 Amphotec ................................................................................................................ 35
                                           5.5.18 PegIntron ................................................................................................................. 35
                                           5.5.19 Oncaspar ................................................................................................................. 37
                                           5.5.20 Epaxal ..................................................................................................................... 38
                                           5.5.21 Elestrin .................................................................................................................... 38
                                     6 Nanotechnology in Drug Delivery – Trend Analysis................................................................... 40
                                        6.1    Increasing Government Funding for Nanotechnology R&D ............................................ 40
                                        6.2    Increasing Seed and Early-Stage Venture Capital .......................................................... 40
                                        6.3    Creation of a New Registration Category for Nanotechnology Products within the USPTO
                                                ........................................................................................................................................ 40
                                        6.4    Genericization and Emerging Business Models Driving a Need for Novel Drug Delivery
                                               Methods .......................................................................................................................... 41
                                     7 Nanotechnology in Drug Delivery – Regulatory Landscape ...................................................... 42
                                        7.1    Introduction ..................................................................................................................... 42
                                        7.2    Europe ............................................................................................................................ 44
                                           7.2.1       REACH Regulation .................................................................................................. 44
                                           7.2.2       European Medicines Agency ................................................................................... 46
                                        7.3    The US ............................................................................................................................ 46
                                           7.3.1       Environment Protection Agency .............................................................................. 46
                                           7.3.2       Food and Drug Administration ................................................................................. 47
                                           7.3.3       National Institute of Occupational Safety and Health............................................... 47
                                        7.4    Japan .............................................................................................................................. 48
                                     8 Nanotechnology in Drug Delivery – Pipeline Analysis ............................................................... 49
                                        8.1    Overview ......................................................................................................................... 49
                                           8.1.1       Pipeline Analysis by Phase ..................................................................................... 50
                                     9 Nanotechnology in Drug Delivery – Strategic Consolidations .................................................... 55
                                        9.1    Overview ......................................................................................................................... 55
                                        9.2    Mergers and Acquisitions ................................................................................................ 55
                                           9.2.1       Mergers and Acquisitions by Geography ................................................................. 55
                                           9.2.2       Mergers and Acquisitions by Deal value.................................................................. 56
                                           9.2.3       Mergers and Acquisition Analysis by Deal Type ...................................................... 57
                                        9.3    Summary of Major M&A Deals ........................................................................................ 58
                                           9.3.1       AstraZeneca Acquires MedImmune ........................................................................ 58
                                           9.3.2       Pfizer Completes Acquisition of Wyeth .................................................................... 58
                                           9.3.3       Celgene Announces To Acquire Abraxis BioScience .............................................. 58
                                           9.3.4       Amgen Acquires Abgenix ........................................................................................ 59
                                           9.3.5       Teva Pharmaceutical Acquires Ivax ........................................................................ 59
                                        9.4    Licensing Agreement ...................................................................................................... 60
                                           9.4.1       Deals by Year of Consolidations.............................................................................. 60
                                           9.4.2       Deals by Geography ................................................................................................ 61
                                           9.4.3       Deals by Deal value................................................................................................. 62
                                        9.5    Summary of Major M&A Deals ........................................................................................ 62
                                           9.5.1       AstraZeneca Enters Into Collaboration and Licensing Agreement with Targacept .. 62
                                           9.5.2       AstraZeneca Enters into Licensing Agreement with Rigel Pharmaceuticals............ 63
                                           9.5.3       Isis Pharmaceuticals Enters Into Licensing Agreement with Genzyme ................... 63
                                           9.5.4       Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca ............... 63
                                           9.5.5       Abraxis Enters Into License Agreement With ProMetic Life Sciences ..................... 64
                                     10 Nanotechnology in Drug Delivery – Future Players ................................................................... 65
                                        10.1 Overview ......................................................................................................................... 65
                                        10.2 Abraxis Bioscience (Abraxis) .......................................................................................... 66
                                           10.2.1 Overview ................................................................................................................. 66
                                           10.2.2 Business Description ............................................................................................... 66
                                           10.2.3 Product Portfolio ...................................................................................................... 67


Nanotechnology in Drug Delivery - Technological Improvements                                                                            GBIHC043MR / Published DEC 2010
and Novel Approaches to Fulfill High Potential
                                                                                                                                                                                 Page 4
                                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                        10.3 AlphaRx Corporation....................................................................................................... 68
                                           10.3.1 Overview ................................................................................................................. 68
                                           10.3.2 Business Description ............................................................................................... 68
                                           10.3.3 Product Portfolio ...................................................................................................... 69
                                        10.4 Camurus AB.................................................................................................................... 69
                                           10.4.1 Overview ................................................................................................................. 69
                                           10.4.2 Product Portfolio ...................................................................................................... 70
                                        10.5 Eurand ............................................................................................................................ 70
                                           10.5.1 Overview ................................................................................................................. 70
                                           10.5.2 Business Description ............................................................................................... 70
                                           10.5.3 Product Portfolio ...................................................................................................... 71
                                        10.6 NanoBio Corporation ...................................................................................................... 71
                                           10.6.1 Overview ................................................................................................................. 71
                                           10.6.2 Product Portfolio ...................................................................................................... 72
                                        10.7 NanoCarrier .................................................................................................................... 72
                                           10.7.1 Overview ................................................................................................................. 72
                                           10.7.2 Product Portfolio ...................................................................................................... 73
                                     11 Nanaotechnology in Drug Delivery – Appendix ......................................................................... 74
                                        11.1 Market Definitions ........................................................................................................... 74
                                        11.2 Abbreviations .................................................................................................................. 74
                                        11.3 Research Methodology ................................................................................................... 75
                                           11.3.1 Coverage ................................................................................................................. 76
                                           11.3.2 Secondary Research ............................................................................................... 76
                                           11.3.3 Primary Research .................................................................................................... 76
                                           11.3.4 Expert Panel Validation ........................................................................................... 77
                                        11.4 Contact Us ...................................................................................................................... 77
                                        11.5 Disclaimer ....................................................................................................................... 77
                                        11.6 Sources ........................................................................................................................... 77




Nanotechnology in Drug Delivery - Technological Improvements                                                                       GBIHC043MR / Published DEC 2010
and Novel Approaches to Fulfill High Potential
                                                                                                                                                                         Page 5
                                                                                      © GBI Research. This is a licensed product and is not to be photocopied
                                     1.1       List of Tables
                                     Table 1: Elan Pharmaceutical, Drugs Based on NanoCrystal Technology, 2010 ............................ 15
                                     Table 2: Nanotechnology in Drug Delivery, Global, Regulatory Filing Clinical Pipeline, 2010 ........ 50
                                     Table 3: Nanotechnology in Drug Delivery, Global, Phase III Clinical Pipeline, 2010 .................... 51
                                     Table 4: Nanotechnology in Drug Delivery, Global, Phase II Clinical Pipeline, 2010 ..................... 51
                                     Table 5: Nanotechnology in Drug Delivery, Global, Phase I Clinical Pipeline, 2010 ...................... 52
                                     Table 6: Nanotechnology in Drug Delivery, Global, Preclinical Pipeline, 2010 ............................... 53
                                     Table 7: Nanotechnology in Drug Delivery, Global, Discovery Pipeline, 2010 ............................... 54
                                     Table 8: Abraxis BioScience, Inc., Nano-Enabled Drug Delivery Pipeline Products, 2010.............. 67
                                     Table 9: AlphaRx Corporation, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010.......... 69
                                     Table 10: Camurus AB, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 ..................... 70
                                     Table 11: Eurand, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 .............................. 71
                                     Table 12: NanoBio Corporation, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 ........ 72
                                     Table 13: NanoCarrier, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 ...................... 73


                                     1.2       List of Figures
                                     Figure 1: Nanotechnology in Drug Delivery, Comparison of General and Nano-enabled Drugs,
                                                2010 ................................................................................................................................. 7
                                     Figure 2: Nanotechnology in Drug Delivery, Current Application of Nanotechnology in the
                                                Pharmaceutical Industry, 2010 ......................................................................................... 9
                                     Figure 3: Nanotechnology in Drug Delivery, Future Application of Nanotechnology in Drug
                                                Pharmaceutical Industry, 2010 ....................................................................................... 11
                                     Figure 4: Nanotechnology in Drug Delivery, Global, Driver and Restraints, 2010 ........................... 17
                                     Figure 5: Nanotechnology in Drug Delivery, Opportunity and Unmet Needs, 2010......................... 19
                                     Figure 6: Nanotechnology in Drug Delivery, Trend Analysis, 2010 ................................................. 40
                                     Figure 7: Nanotechnology in Drug Delivery, Challenges Facing Regulators Regarding
                                                Nanotechnology ............................................................................................................. 43
                                     Figure 8: Nanotechnology in Drug Delivery, Global, Pipeline by Therapy Area (%), 2010 .............. 49
                                     Figure 9: Nanotechnology in Drug Delivery, Global, Pipeline by Phase (%), 2010 ......................... 50
                                     Figure 10: Nanotechnology in Drug Delivery, Global, M&A Deals by Geography (%), (2006-2010)
                                                ....................................................................................................................................... 55
                                     Figure 11: Nanotechnology in Drug Delivery, Global, M&A Deals by Deals Value (%), 2006-201056
                                     Figure 12: Nanotechnology in Drug Delivery, Global, M&A Deals by Deals Type (%), 2006-2010 57
                                     Figure 13: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Years of
                                                Consolidation (%), 2006-2010 ........................................................................................ 60
                                     Figure 14: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Geography (%),
                                                2006-2010 ...................................................................................................................... 61
                                     Figure 15: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Deals Value (%),
                                                2006-2010 ...................................................................................................................... 62
                                     Figure 16: Nanotechnology in Drug Delivery, Global, Clinical Pipeline by Company, 2010 ............ 65




Nanotechnology in Drug Delivery - Technological Improvements                                                                           GBIHC043MR / Published DEC 2010
and Novel Approaches to Fulfill High Potential
                                                                                                                                                                                Page 6
                                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                     2      Nanotechnology in Drug Delivery – Introduction
                                     2.1    Introduction
                                     Nanotechnology witnesses a lot of attention with the never-seen-before interest because of its
                                     future growth potential. This is because it can revolutionize the areas in which it is being exploited.
                                     In the pharmaceutical market, nanotechnology is just starting to make an impact. The application of
                                     nanotechnology in drug delivery systems has the ability to manipulate molecules for manufacturing
                                     devices with programmed functions. The current pharmaceutical market has many drugs, which
                                     use nanotechnology in their drug delivery approaches. These nano-enabled systems include
                                     liposomes, polymeric micelles, nanoparticles, dendrimers, and nanocrystals.
                                     Liposomes and polymer micelles were first prepared in 1960’s. Following this, nanoparticles and
                                     dendrimers were prepared in the 1970’s. The conjugation of colloidal gold particles with antibody to
                                     target specific staining during 1980’s, is considered as a precursor of recent widespread use of
                                     gold particles in nanotechnology.
                                     GBI research analysis suggests that the nano-enabled drug delivery market will witness a high
                                     growth in the future. The high growth in the nano-enabled drug delivery market is primarily because
                                     of increasing acceptance of nano-enabled drugs, promising nano-enabled drugs in the pipeline
                                     portfolio and increased governmental funding in the nanotechnology research. In addition to these,
                                     rapidly increasing interest in nanotech R&D, and increased availability of seed and early-stage
                                     venture capital will drive the market during the forecast period.
                                     GBI Research analysis shows that significant opportunities exist at the intersection of
                                     nanotechnology and traditional pharmaceutical R&D, though much uncertainty remains on how this
                                     will affect the industry. GBI Research suggests the dosing benefits of nano-enabled drug delivery
                                     systems have a great potential in treating both infectious disease and cancer.

                                      Figure 1: Nanotechnology in Drug Delivery, Comparison of General and Nano-enabled
                                                Drugs, 2010


                                                 Parameters                      General Drug                       Nano-Enabled Drug


                                                  Bioavailability                     Low                                  High


                                                  Specificity
                                                                                      Low                                  High



                                                   Solubility                         Low                                Improved


                                                   Efficacy                           Low                                  High


                                                   Safety                             Low                                  High


                                           Liver and Renal Toxicity                   Low                                  High



                                              Pharmacokinetics                        Low                                Improved


                                            Patients Compliance                       Low                                  High



                                      Source: GBI Research




Nanotechnology in Drug Delivery - Technological Improvements                                               GBIHC043MR / Published DEC 2010
and Novel Approaches to Fulfill High Potential
                                                                                                                                        Page 7
                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                     2.2     GBI Research Report Guidance
                                     ·     The report starts with an executive summary of the key points influencing the global nano-
                                           enabled drug delivery market.
                                     ·     The chapter titled Nanotechnology in Drug Delivery details the current and future potential
                                           application of nanotechnology in drug delivery systems.
                                     ·     The next chapter analyzes the major nano-enabled drug delivery technology case studies.
                                     ·     The chapter titled Nanotechnology in Drug Delivery- Market Characterization analyzes the
                                           market drivers and restrains. This chapter also analyzes opportunities and unmet needs in the
                                           nano-enabled drug delivery market, and product profiles of major marketed products.
                                     ·     The chapter titled Nanotechnology in Drug Delivery- Trend Analysis analyzes prevailing and
                                           upcoming trends and its effects on the market.
                                     ·     The chapter titled Nanotechnology in Drug Delivery- Regulatory landscape analyzes regulatory
                                           acceptance and guidelines in different geographical regions. This section also analyzes the
                                           regulatory challenges in nano-enabled drug delivery system market.
                                     ·     The chapter titled Nanotechnology in Drug Delivery- Pipeline Analysis provides pipeline
                                           analysis for nano-enabled drug delivery. This section includes detailed analysis of the top
                                           companies operating in the market.
                                     ·     The chapter titled Nanotechnology in Drug Delivery: Strategic Consolidations talks in detail
                                           about the strategic consolidations that have taken place within the nano-enabled drug delivery
                                           market. An analysis of the key licensing agreements is also given with an increasing focus on
                                           geographies.
                                     ·     The chapter titled Nanotechnology in Drug Delivery: Future Players talks in detail about the
                                           companies, which have strong pipeline candidates.




Nanotechnology in Drug Delivery - Technological Improvements                                               GBIHC043MR / Published DEC 2010
and Novel Approaches to Fulfill High Potential
                                                                                                                                        Page 8
                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                     3         Application of Nanotechnology in Drug Delivery
   Nano-carriers and nano-
   engineered drugs are              3.1       Current Applications of Nano-enabled Drug Delivery
   widely used in drug
   delivery systems                  3.1.1      Nano-engineered drugs
                                     3.1.1.1     Nano Crystals
                                     These are single crystalline nano materials which has at least one dimension on the order of
                                     100nm. Nano crystals have a wide range of proven and potential applications in different fields.
                                     Elan Pharma International Ltd. has FDA approval on a NanoCrystal technology in 2000. The
                                     technology improves the bioavailability of Wyeth’s drug sirolimus. The new formulation Rapamune
                                     overcame the drug’s relative insolubility by reducing the particle size to less than 200nm.
                                     3.1.1.2     Nano Suspensions
                                     The poor water solubility of drugs is a major problem for drug formulation which leads to low
                                     bioavailability and erratic absorption. There are a number of formulation approaches to resolve the
                                     problems of low solubility and low bioavailability. The reduction of drug particles into the sub-micron
                                     range leads to a significant increase in the dissolution rate and therefore enhances bioavailability.
                                     Nano suspensions are candidates that can be used to increase the dissolution of drugs that are
                                     poorly soluble in water. Nano suspensions contain submicron colloidal dispersion of
                                     pharmaceutical active ingredient particles in a liquid phase stabilized by surfactants.

                                      Figure 2: Nanotechnology in Drug Delivery, Current Application of Nanotechnology in the
                                                Pharmaceutical Industry, 2010



                                                    Nanocrystals-                                                  •Carbon & Ceramic
                                                    Increased surface                                              Nanostructures
                                                    area
                                                                                                                   •Dendrimers-
                                                                                                                   Increased drug load



                                                                                      Current
                                                                                   Applications of
                                                                                   Nanotechnology




                                                                                                                   •Liposomes- Targeted
                                                    Nanosuspensions-                                               drug delivery
                                                    Increased
                                                    bioavailability                                                •Mycelles and
                                                                                                                   polymeric
                                                                                                                   Nanoparticles



                                      Source: GBI Research




Nanotechnology in Drug Delivery - Technological Improvements                                               GBIHC043MR / Published DEC 2010
and Novel Approaches to Fulfill High Potential
                                                                                                                                          Page 9
                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                     3.1.2     Nano-carriers
                                     3.1.2.1    Carbon and Ceramic Nanostructures
                                     The carbon-based nanostructures include carbon nanotubes, carbon nano particles, and porous
                                     carbons, activated carbon fibers and carbon aerogels. Among these carbon nanotubes are
                                     presently the most attractive carbon nanostructured material being researched in the
                                     pharmaceutical market. The carbon nanotubes are allotropes of carbon with a cylindrical
                                     nanostructure. Ceramic nanostructures are used in biomedical implants.
                                     3.1.2.2    Dendrimers
                                     Dendrimers are monodisperse macromolecules, which fall under a new class of polymeric
                                     materials. These are repeatedly branched and roughly spherical large molecules with very high
                                     symmetry. These unique behaviors make dendrimers a suitable candidate for a wide range of
                                     biomedical and industrial applications. Applications mainly involve conjugation of other chemical
                                     species to the dendrimer surface that can function as detecting agents, imaging agents, and
                                     pharmaceutically active compounds. Dendrimers provide a multivalent system that is exploited in a
                                     number of drug delivery systems.
                                     3.1.2.3    Liposomes
                                     Liposomes are concentric bilayered structures made of amphipathic phospholipids. The Liposomes
                                     are classified as multilamellar (MLV), small unilamellar (SUVs), and large unilamellar (LUV
				
DOCUMENT INFO
Shared By:
Stats:
views:236
posted:1/26/2011
language:English
pages:77
Description: Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential Summary GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues in Nanotechnology in Drug Delivery market. The report provides a comprehensive insight into the role of Nanotechnology in Drug Delivery. The report also provides a detailed analysis of market characterization of nanotechnology in drug delivery market in terms of its market size, segmentation by key geography types and the major market drivers and barriers. The report also talks about the technological trends over the years in use of nanotechnology in drug delivery. Scope The scope of the report includes - - Detailed overview of Nanotechnology in Drug Delivery in pharmaceutical industry along with their use, efficiency and limitation. - Annualized market data from 2007 and forecast forward till 2016 along with segmentation by geography. - Key market drivers and restraints shaping the Nanotechnology in Drug Delivery market. - Competitive landscape analysis with competitive profiling of leading companies. - Analysis of partnership deals from 2006 to 2010 - Analysis of M&A deals from 2005 to 2010 along with segmentation by value geography and companies. Reasons to buy The report will enhance your decision making capability. It will allow you to - - Develop better strategies for Nanotechnology in Drug Delivery market by understanding the market dynamics. - Develop market-entry and market expansion strategies by identifying the key development area - Understand the factors shaping the Nanotechnology in Drug Delivery - For understanding the technological trends in the market. - Identify the key players best positioned to take the advantage of the opp
BUY THIS DOCUMENT NOW PRICE: $3500 100% MONEY BACK GUARANTEED
PARTNER GBI Research
GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs. Headquartered in the UK, the company has branches in the US and Asia, and provides world class client support and service.